AimTop Ventures

ChainOpera is a technology company that specializes in developing a decentralized AI platform and ecosystem. This platform aims to democratize AI development by enabling users to collaboratively create and own decentralized AI applications and agents. It operates on a secure blockchain infrastructure, offering a decentralized exchange for trading cryptocurrencies and digital assets with enhanced privacy and security. Users have full control over their funds and can co-create and co-own AI agents and applications within this ecosystem.

TensorOpera is an artificial intelligence company based in Silicon Valley, focused on building scalable, secure AI platforms for enterprises and developers. Its flagship offerings include the TensorOpera AI Platform, a comprehensive generative AI ecosystem that supports model deployment and serving, AI agent APIs, and workflows for training and inference on serverless or decentralized GPU resources, with emphasis on security and privacy. The TensorOpera FedML platform advances federated learning and analytics, providing zero-code deployment, an edge AI SDK for devices, and an MLOps layer to streamline decentralized ML workflows. In addition, TensorOpera offers a community-building platform that enables decentralization, deployment, and productization of generative AI applications, helping developers and enterprises commercialize AI solutions without centralizing data in the cloud. The company emphasizes decentralization, edge computing, and practical tools to operationalize AI at scale while maintaining data privacy.

GruEnergy manufactures silicon-based anode materials for the electrification of autos, power tools, and other consumer goods.

FEDML Nexus AI® (https://nexus.fedml.ai) is a next-generation cloud platform that enables developers and enterprises to easily, economically, and securely build, deploy, and monetize their large language models (LLMs) and other generative AI models. It provides holistic support with a large-scale distributed GPU cloud (multi-cloud and multi-provider), high-performance ML libraries, user-friendly AIOps, and LLM and AI Agent studios.

Artly Coffee, founded in 2020 and based in Seattle, Washington, operates hybrid coffee stores that feature a robot barista. This innovative approach combines artificial intelligence and computer vision to create specialty coffee. The robot barista learns various coffee-making techniques from expert human baristas, ensuring high-quality beverages. Customers can customize and place their orders through an application, which the robots process, thereby reducing the risks associated with human contact and enhancing public health safety. Artly Coffee's unique blend of technology and coffee craftsmanship sets it apart in the specialty coffee market.

Phyla is a biotechnology company focused on developing alternative therapies for treating acne through innovative microbiome technology. Unlike traditional methods that aim to introduce beneficial bacteria, Phyla's approach centers on selectively removing harmful bacteria from the skin microbiome using bacteriophages. This subtractive method seeks to rebalance the microbiome, promoting a healthy state without damaging beneficial strains. Phyla's product line offers a minimalist skincare system designed to effectively address acne while minimizing skin damage, thus providing customers with a more targeted and gentle treatment option.

PolyExplore Inc., established in 2016 and headquartered in San Jose, California, specializes in developing inertial navigation solutions. Its product portfolio includes RTK GNSS/INS systems, mobile sensor fusion solutions, and mobile mapping solutions, catering to industries such as autonomous driving, HD mapping, marine unmanned vehicles, infrastructure maintenance, precision agriculture, construction, mining, and high-speed trains.

TriagingX, based in Silicon Valley, specializes in developing advanced threat detection software aimed at protecting endpoint systems and data center servers from zero-day attacks. The company originally created a pioneering malware sandbox utilized by numerous Fortune 500 companies for daily malware analysis. Currently, TriagingX is advancing its technology by building the next generation of sandboxes and a larger-scale analytics system that integrates malware behavior outputs, endpoint snapshots, network logs, and data from various security products. This comprehensive approach is designed to enhance the detection and response capabilities of businesses, allowing them to identify and rectify vulnerabilities in their networks proactively. TriagingX's mission is to collaborate closely with clients to ensure they remain one step ahead of potential threats and to fortify their defenses against sophisticated attacks.

Helios Data is a company that specializes in enhancing data management for data-rich enterprises by utilizing innovative network technologies and advanced artificial intelligence. The firm offers a platform designed for data insight sharing, which facilitates data analytics and monetization while ensuring data transparency, privacy, and security. Helios Data's solution enables organizations to visualize critical data usage against AI-assisted behavior benchmarks, helping them navigate the complexities of personal data management. By promoting a data-centric architecture, the company simplifies compliance with privacy regulations and enhances secure data collaboration, ultimately allowing enterprises to transform their data handling practices through automation and continuous visibility.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Oculii Corp., based in Beavercreek, Ohio, specializes in developing advanced radar sensors and AI software for various applications, including intelligent transportation, automotive, aerial, and consumer sectors. The company's key products are radar sensors that provide real-time 4D tracking information, enabling accurate 3D positioning and speed detection. These sensors are used in automotive safety systems, traffic management, airborne and medical applications, as well as automated speed enforcement systems. Oculii's innovative Virtual Aperture Imaging radar technology enhances radar resolution without increasing the physical size of the sensor, making it more affordable and scalable. The company collaborates with industry leaders to deliver high-performance, all-weather, and low-cost perception technology for autonomous systems.

Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.

NEXT Trucking, Inc. is a logistics technology company that operates an online platform connecting shippers with carriers for freight and cargo transportation. Founded in 2015 and headquartered in El Segundo, California, the company provides a mobile application and web solution featuring a trucking marketplace where truckers can offer their services by posting preferred routes and pay rates. The platform facilitates direct connections between carriers and shippers, enabling efficient pick-up and delivery arrangements while reflecting real-time trucker availability. Additionally, NEXT Trucking offers digital paperwork, fleet management tools, online payment processing, and real-time tracking to enhance operational transparency and efficiency. The company serves a diverse range of clients across North America, including some of the world's leading businesses, and is recognized as a pioneer in the FreightTech sector.

CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.